Phenylephrine extended-release

Drug Profile

Phenylephrine extended-release

Alternative Names: Phenylephrine extended-release - Schering-Plough; Phenylephrine HCl extended-release; Phenylephrine hydrochloride extended-release; SCH-002063

Latest Information Update: 11 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Schering-Plough
  • Developer Bayer
  • Class Antihypotensives; Decongestants; Ethanolamines; Mydriatics; Small molecules; Urologics
  • Mechanism of Action Alpha 1 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Seasonal allergic rhinitis

Most Recent Events

  • 31 Oct 2011 Bayer completes a phase III trial for Seasonal allergic rhinitis in USA (NCT01413958)
  • 20 Oct 2011 Merck Sharp & Dohme completes enrolment in its phase III trial for Seasonal allergic rhinitis in USA (NCT01413958)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top